The patent significantly strengthens Bonum’s intellectual property protecting its Dual-Binding Antibody platform for conditionally regulated therapeutics for a broad range of pairs, including but not limited to LRRC15-IFNa, PD-L1-IFNa, and PD1-IL2
News Archive
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…
Bonum Therapeutics Appoints Samuel C. Blackman, MD, PhD, to its Board of Directors
We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
GeekWire
July 18, 2024
Media
Bonum Therapeutics to double its space in Eastlake after move
Puget Sound Business Journal
July 21, 2024
Media
Bonum Therapeutics to Present Posters and a Short Talk on its Novel Platform for Generating Conditionally Activated Targeted Therapies at Keystone Conference
“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program…”